Fortitude Family Office’s Prime Medicine PRME Stock Holding History

Fortitude Family Office’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$904	Sell	296 -12	-4%	-$40	﹤0.01%	2276
2026 Q2	$1.14K	Sell	308 -128	-29%	-$425	﹤0.01%	1706
2026 Q1	$1.52K	Buy	436 +140	+47%	+$533	﹤0.01%	1377
2025 Q4	$1.03K	Hold	296	–	–	﹤0.01%	1436
2025 Q3	$1.64K	Hold	296	–	–	﹤0.01%	1337
2025 Q2	$731	Buy	+296	New	+$456	﹤0.01%	1646

Other funds holding PRME

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.64% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Fortitude Family Office's PRME Position: Q3 2026 in Review

Fortitude Family Office reduced its Prime Medicine (PRME) stake by 3.9% in Q3 2026, selling an estimated $40 and leaving 296 shares worth $904. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

Fortitude Family Office first reported a position in PRME in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.64K in Q3 2025. 6 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Fortitude Family Office held 296 shares of Prime Medicine worth $904 as of Q3 2026.
Fortitude Family Office sold 12 Prime Medicine shares in Q3 2026, an estimated $40.
Prime Medicine made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2276 holding.
Fortitude Family Office first reported a position in Prime Medicine in Q2 2025 and has held it in 6 quarters since.
Fortitude Family Office's Prime Medicine position peaked at $1.64K in Q3 2025.
6 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.